豚由来ワクチン市場：適応症別、技術別、エンドユーザー別-2024-2030年の世界予測

豚由来ワクチン市場規模は2023年に17億1,000万米ドルと推定され、2024年には18億2,000万米ドルに達し、CAGR 6.72%で2030年には27億米ドルに達すると予測されています。

豚由来ワクチンは、豚の様々な疾病を予防するための免疫学的製剤です。これらのワクチンはブタの免疫系を刺激し、病気の原因となるウイルスや細菌などの病原体に対する防御機能を発達させるために作られます。感染を模倣することで、将来、実際の病原体に遭遇した場合に、豚の体がその病原体を認識し、闘えるように準備するのです。豚の病気の発生率の上昇と、豚肉製品の世界の消費量の増加が、豚由来ワクチンを必要とする大きな原動力となっています。さらに、補助金や啓発プログラムなど、政府の支援策がワクチンの使用を後押ししています。しかし、コールドチェーン・インフラが必要であるため、特に発展途上国では物流上の課題が生じる。さらに、豚の品種によって免疫応答にばらつきがあるため、ワクチンの有効性に影響を及ぼし、豚由来ワクチンの開発・導入のハードルとなる可能性があります。しかし、主なプレーヤーは、豚由来ワクチンの性能課題を克服できるカスタマイズされたワクチンの開発を確実にするために、ナノテクノロジー、遺伝子編集戦略、精密医療などの新技術を模索しています。さらに、安全性を損なうことなく免疫反応を高める新しいアジュバントを研究し、針を使わない投与法を開発することで、ワクチンの取り込みを改善し、動物へのストレスを軽減できる可能性があります。

技術遺伝子工学と分子生物学技術の進歩により、組み換えワクチンの技術革新が進む

結合型ワクチン（conjugate vaccine）とは、多糖体抗原をキャリア分子に融合または結合させたワクチンです。豚由来ワクチンでは、一般的に免疫原性が低い多糖類を病原体が持つ疾患を対象とするために使用されます。このようなワクチンは、多糖類のカプセルを持つ細菌に起因する疾患を標的とする場合に特に有用です。DNAワクチンは免疫反応を誘導するために遺伝物質を利用します。遺伝物質が動物の細胞に入ると、抗原の産生に利用され、免疫系を刺激します。これらのワクチンは、獣医学分野ではまだ比較的新しいです。このようなワクチンは、迅速な開発が可能であり、アジュバントを必要とせずに長期間の免疫を提供できるため、好まれる可能性があります。不活化ワクチンには、死滅した病原体が含まれています。感染症を引き起こすことはありませんが、免疫反応は起こります。これらのワクチンは安全で安定していると考えられています。弱毒生ワクチンは、病原体を生きたまま弱毒化したものです。自然感染を忠実に模倣しており、通常、強力で長期間持続する免疫が得られます。遺伝子組換えワクチンは、遺伝子工学の技術を用いて作られた病原体の一部（通常はタンパク質）を使用します。この成分は、生きた病原体を持ち込むリスクなしに免疫反応を刺激するために使用されます。トキソイドワクチンは、特定の細菌が産生する毒素を不活化することによって作られます。これらのワクチンは、細菌そのものではなく、細菌が産生する毒素によって引き起こされる病気から身を守るために使用されます。トキソイドワクチンは、細菌毒素が主な原因となる疾病に対処する際に望ましい選択肢です。

エンドユーザー：養豚場での集団ワクチン接種プログラムのニーズの高まり

養豚/豚生産農場セクターには、主に食肉生産を目的とした豚の飼育に携わる事業体が含まれます。このような農場におけるワクチンのニーズは、疾病のない環境を維持し、家畜の成長性能を高め、最終的に農家の収益性を向上させるという要件によってもたらされています。豚や豚の生産農場では通常、豚繁殖・呼吸器症候群（PRRS）、豚インフルエンザ、口蹄疫など、一般的な豚の病気に幅広く対応できるワクチンが必要です。動物病院や診療所は、豚を含む広範な動物に対応しています。これらの施設では一般的に、定期的な健康診断や特定の疾病発生の一環として、ワクチン接種のために豚やその他の豚に遭遇します。このような環境では、幅広い効能を持ち、免疫の発現が早いワクチンが好まれます。このような施設では、個体または小規模の群れを対象としているため、単回投与で投与が容易なワクチンや、より小さなパッケージサイズのワクチンを好むことが多いです。

地域別インサイト

南北アメリカ、特に米国とカナダでは、養豚業が盛んで動物の健康管理に重点を置いているため、豚ワクチン市場が確立されています。同国では、豚繁殖・呼吸器症候群（PRRS）、豚インフルエンザなどの流行性疾患に対するワクチン接種に対する消費者のニーズが高いです。生産者は最新のワクチンを採用することが多く、購買行動は豚群のための先進的なソリューションに投資する用意があることを示しています。米国では最近、有効性が向上し、免疫期間が長くなるワクチンの開発に重点を置いた研究が進められています。バイオテクノロジー企業への投資や、米国農務省（USDA）-動植物検疫局（APHIS）傘下の動物用生物製剤プログラム（Veterinary Biologics Program）のような政府の取り組みは、この分野を強化するための継続的な取り組みを反映しています。EMEA諸国は、動物福祉と衛生に関する規制が厳しい多様な市場です。欧州の消費者は高い安全基準を満たすワクチンを求めており、品質が保証されたワクチンへの需要が高まっています。EUのHorizon 2020プログラムでは、豚の疾病に対応する研究に多額の投資が行われており、これが新しく効率的なワクチンの開発を後押ししています。APAC地域では、中国が豚肉市場を高度に発展させ、豚肉市場の必要性を高めています。APAC地域で養豚業が勃興しているインドは、中程度ながら豚由来ワクチンの需要が伸びています。消費者のニーズは、コストに敏感な購買行動により、手頃な価格で入手可能なワクチンを中心に展開されています。政府は、予防接種や動物衛生プログラムを支援するイニシアティブを通じて養豚産業の成長を奨励しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、豚由来ワクチン市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、豚由来ワクチン市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.豚由来ワクチン市場の市場規模および予測は？

2.豚由来ワクチン市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.豚由来ワクチン市場の技術動向と規制枠組みは？

4.豚由来ワクチン市場における主要ベンダーの市場シェアは？

5.豚由来ワクチン市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で豚の病気の蔓延が増加
    • 高品質の豚肉の需要増加
    • 動物の健康を支援する政府の取り組み
  • 抑制要因
    • 豚ワクチン開発の高コストと複雑な保管問題
  • 機会
    • 豚ワクチンの技術的進歩
    • 小説の制作に有利な投資情勢豚由来ワクチン
  • 課題
    • 豚由来ワクチンに関連する副作用とともに、入手性および認知度の制限
• 市場セグメンテーション分析
  • テクノロジー：遺伝子工学と分子生物学技術の進歩により、組み換えワクチンの革新が進む
  • エンドユーザー：豚生産農場における集団ワクチン接種プログラムの必要性の高まり
• 市場動向分析
• ロシア・ウクライナ紛争の累積的影響
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 豚由来ワクチン市場適応症別

• 関節炎
• 下痢
• 豚サーコウイルス関連疾患
• 豚繁殖呼吸器症候群
• 豚インフルエンザ

第7章 豚由来ワクチン市場：技術別

• 結合ワクチン
• DNAワクチン
• 不活化ワクチン
• 生弱毒化ワクチン
• 組み換えワクチン
• トキソイドワクチン

第8章 豚由来ワクチン市場：エンドユーザー別

• 養豚農場
• 獣医クリニック/病院

第9章 南北アメリカの豚由来ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の豚由来ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの豚由来ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • ゾエティスが英国でサーコマックスを発売
  • メルクアニマルヘルス、3-in-1豚ワクチンを発売
  • エランコはアプティミューンのPRRS不活化自家ワクチンの米国独占販売代理店です

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. PORCINE VACCINES MARKET RESEARCH PROCESS
• FIGURE 2. PORCINE VACCINES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. PORCINE VACCINES MARKET DYNAMICS
• FIGURE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PORCINE VACCINES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PORCINE VACCINES MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL PORCINE VACCINES MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL PORCINE VACCINES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL PORCINE VACCINES MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL PORCINE VACCINES MARKET SIZE, BY ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL PORCINE VACCINES MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL PORCINE VACCINES MARKET SIZE, BY DIARRHEA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS ASSOCIATED DISEASE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE CIRCOVIRUS ASSOCIATED DISEASE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL PORCINE VACCINES MARKET SIZE, BY PORCINE REPRODUCTIVE & RESPIRATORY SYNDROME, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL PORCINE VACCINES MARKET SIZE, BY SWINE INFLUENZA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL PORCINE VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL PORCINE VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL PORCINE VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL PORCINE VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL PORCINE VACCINES MARKET SIZE, BY RECOMBINANT VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL PORCINE VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL PORCINE VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOG/PIG PRODUCTION FARM, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL PORCINE VACCINES MARKET SIZE, BY HOG/PIG PRODUCTION FARM, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY CLINICS/HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL PORCINE VACCINES MARKET SIZE, BY VETERINARY CLINICS/HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. AMERICAS PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 40. AMERICAS PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 41. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 42. AMERICAS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 43. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 44. AMERICAS PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 45. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 46. AMERICAS PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 47. ARGENTINA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 48. ARGENTINA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 49. ARGENTINA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 50. ARGENTINA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 51. ARGENTINA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 52. ARGENTINA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 53. BRAZIL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 54. BRAZIL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 55. BRAZIL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 56. BRAZIL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 57. BRAZIL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 58. BRAZIL PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 59. CANADA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 60. CANADA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 61. CANADA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 62. CANADA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 63. CANADA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 64. CANADA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 65. MEXICO PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 66. MEXICO PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 67. MEXICO PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 68. MEXICO PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 69. MEXICO PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 70. MEXICO PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 71. UNITED STATES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 72. UNITED STATES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 73. UNITED STATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 74. UNITED STATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 75. UNITED STATES PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 76. UNITED STATES PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 77. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 78. UNITED STATES PORCINE VACCINES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 79. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 80. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 82. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 84. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 86. ASIA-PACIFIC PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 87. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 90. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 91. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 92. AUSTRALIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 93. CHINA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 94. CHINA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 95. CHINA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 96. CHINA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 97. CHINA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 98. CHINA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 99. INDIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. INDIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. INDIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 102. INDIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 103. INDIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 104. INDIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 105. INDONESIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 106. INDONESIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 107. INDONESIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 108. INDONESIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 109. INDONESIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 110. INDONESIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 111. JAPAN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 112. JAPAN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 113. JAPAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 114. JAPAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 115. JAPAN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 116. JAPAN PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 117. MALAYSIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 118. MALAYSIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 119. MALAYSIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 120. MALAYSIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 121. MALAYSIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 122. MALAYSIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 123. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 126. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 127. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 128. PHILIPPINES PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 129. SINGAPORE PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 130. SINGAPORE PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 131. SINGAPORE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 132. SINGAPORE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 133. SINGAPORE PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 134. SINGAPORE PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 135. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 138. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 140. SOUTH KOREA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 141. TAIWAN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 142. TAIWAN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 143. TAIWAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 144. TAIWAN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 145. TAIWAN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 146. TAIWAN PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 147. THAILAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 148. THAILAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 149. THAILAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 150. THAILAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 151. THAILAND PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 152. THAILAND PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 153. VIETNAM PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 154. VIETNAM PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 155. VIETNAM PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. VIETNAM PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. VIETNAM PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 158. VIETNAM PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 159. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 160. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA PORCINE VACCINES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 167. DENMARK PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 168. DENMARK PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 169. DENMARK PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 170. DENMARK PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 171. DENMARK PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 172. DENMARK PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 173. EGYPT PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 174. EGYPT PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 175. EGYPT PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 176. EGYPT PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 177. EGYPT PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 178. EGYPT PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 179. FINLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 180. FINLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 181. FINLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 182. FINLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 183. FINLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 184. FINLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 185. FRANCE PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 186. FRANCE PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 187. FRANCE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 188. FRANCE PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 189. FRANCE PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 190. FRANCE PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 191. GERMANY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 192. GERMANY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 193. GERMANY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 194. GERMANY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 195. GERMANY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 196. GERMANY PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 197. ISRAEL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 198. ISRAEL PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 199. ISRAEL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 200. ISRAEL PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 201. ISRAEL PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 202. ISRAEL PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 203. ITALY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 204. ITALY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 205. ITALY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 206. ITALY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 207. ITALY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 208. ITALY PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 209. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 210. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 211. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 212. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 213. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 214. NETHERLANDS PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 215. NIGERIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 216. NIGERIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 217. NIGERIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 218. NIGERIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 219. NIGERIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 220. NIGERIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 221. NORWAY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 222. NORWAY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 223. NORWAY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 224. NORWAY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 225. NORWAY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. NORWAY PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. POLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 228. POLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 229. POLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 230. POLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 231. POLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 232. POLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 233. QATAR PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 234. QATAR PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 235. QATAR PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 236. QATAR PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 237. QATAR PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 238. QATAR PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 239. RUSSIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 240. RUSSIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 241. RUSSIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 242. RUSSIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 243. RUSSIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 244. RUSSIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 245. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 246. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 248. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 250. SAUDI ARABIA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH AFRICA PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 257. SPAIN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 258. SPAIN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 259. SPAIN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 260. SPAIN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 261. SPAIN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 262. SPAIN PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 263. SWEDEN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 264. SWEDEN PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 265. SWEDEN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 266. SWEDEN PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 267. SWEDEN PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 268. SWEDEN PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 269. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 270. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 271. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 272. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 273. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 274. SWITZERLAND PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 275. TURKEY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 276. TURKEY PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 277. TURKEY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 278. TURKEY PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 279. TURKEY PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 280. TURKEY PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 281. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 287. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 288. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 290. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 292. UNITED KINGDOM PORCINE VACCINES MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 293. PORCINE VACCINES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 294. PORCINE VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

[185 Pages Report] The Porcine Vaccines Market size was estimated at USD 1.71 billion in 2023 and expected to reach USD 1.82 billion in 2024, at a CAGR 6.72% to reach USD 2.70 billion by 2030.

Porcine vaccines are immunological preparations designed to prevent various swine diseases in pigs. These vaccines are created to stimulate the porcine immune system, enabling it to develop defenses against pathogens such as viruses or bacteria that can cause illness. By mimicking the infection, they prepare the swine's body to recognize and combat the actual pathogens should they be encountered in the future. The rise in the incidence of swine diseases and the growing global consumption of pork products are major driving factors behind the need for porcine vaccines. Furthermore, supportive government initiatives, including subsidies and awareness programs, have encouraged the use of vaccines. However, the need for a cold chain infrastructure creates logistical challenges, particularly in developing countries. Furthermore, the variability in the immune response of different pig breeds can impact vaccine effectiveness and create hurdles for the development and adoption of porcine vaccines. However, key players are exploring novel technologies such as nanotechnology, gene editing strategies, and precision medicine to ensure the development of customized vaccines that can overcome the performance challenges of porcine vaccines. Moreover, investigating new adjuvants to enhance immune response without compromising safety and developing needle-free administration could improve vaccine uptake and reduce stress on animals.

Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies

A conjugate vaccine refers to a vaccine that is composed of a polysaccharide antigen fused or conjugated to a carrier molecule. In porcine vaccines, they are used to target diseases where the pathogens have polysaccharide coatings, which are generally poorly immunogenic. Such vaccines are especially useful for targeting diseases caused by bacteria with polysaccharide capsules. DNA vaccines utilize genetic material to induce an immune response. When the genetic material enters the animal's cells, it is used to produce the antigen which in turn stimulates the immune system. These vaccines are still relatively novel in the veterinary field. Such vaccines may be preferred for their potential for rapid development and their ability to provide long-lasting immunity without the need for adjuvants. Inactivated vaccines contain pathogens that have been killed. They cannot cause an infection but still prompt an immune response. These vaccines are considered safe and stable. Live attenuated vaccines contain a live and weakened version of the pathogen. They closely mimic a natural infection and typically provide strong, long-lasting immunity. Recombinant vaccines use a piece of the pathogen (typically a protein) created using the techniques of genetic engineering. This component is used to stimulate an immune response without the risk of introducing a live pathogen. Toxoid vaccines are created by inactivating the toxins produced by certain bacteria. These vaccines are used to protect against diseases that are caused not by the bacteria itself, but by the toxins they produce. Toxoid vaccines are the preferred option when addressing illnesses where the primary concern is the bacterial toxin.

End User: Growing need for mass vaccination programs in the hog/pig production farm

The hog/pig production farm sector includes entities involved in raising pigs primarily for meat production. The need for vaccines in such farms is driven by the requirement to maintain a disease-free environment, enhance growth performance of the animals, and ultimately increase farmer profitability. Hog and pig production farms typically require vaccines thar can address a wide spectrum of common swine diseases, such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and foot and mouth disease, among others. Veterinary clinics and hospitals cater to a broad range of animals, including pigs. These facilities generally encounter pigs and other swine for vaccinations as part of routine health checks or specific disease outbreaks. The vaccine preferences in this environment are for products with broad-spectrum efficacy and rapid onset of immunity. Since these facilities might be dealing with individual animals or small herds, they often prefer single-dose, easy-to-administer vaccines that are also available in smaller package sizes.

Regional Insights

In the Americas region, particularly the U.S. and Canada, the porcine vaccine market is well-established due to the extensive pig farming industry and a strong emphasis on animal health management. The country sees a significant consumer need for vaccinations against prevalent diseases such as porcine reproductive and respiratory syndrome (PRRS), swine influenza, and others. Producers often adopt the latest vaccines, and purchasing behavior indicates a readiness to invest in advanced solutions for swine herds. Recent research in the U.S. has focused on developing vaccines with improved efficacy and longer immunity periods. Investments in biotechnology companies and government initiatives such as the Veterinary Biologics Program under the United States Department of Agriculture(USDA)-Animal & Plant Health Inspection Service(APHIS) reflect ongoing efforts to strengthen the sector. The EMEA countries represent a diverse market with stringent animal welfare and health regulations. The European consumer requires vaccines that comply with high safety standards, leading to a demand for quality-assured vaccines. The EU's Horizon 2020 program has seen substantial investments in research addressing swine diseases, which propels the development of new and efficient vaccines. In the APAC region, China represents a highly evolved market for pig meat, thereby accentuating the need for porcine markets. India, with an emerging pig farming industry in the APAC region, presents a moderate but growing demand for porcine vaccines. Consumer needs revolve around affordable and accessible vaccines due to cost-sensitive purchasing behaviors. The government has been encouraging the growth of the swine industry through initiatives that provide support for vaccinations and animal health programs.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Porcine Vaccines Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Porcine Vaccines Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Porcine Vaccines Market, highlighting leading vendors and their innovative profiles. These include Aptimmune Biologics, Inc., Arko Laboratories, AVAC Vietnam Joint Stock Company, Bayer AG, Bimeda Holdings PLC, Biogenesis Bago S.A., Boehringer Ingelheim International GmbH, Ceva Sante Animale, Eli Lilly and Company, Endovac Animal Health, FATRO S.p.A., Formosa Biomedical Inc., Genvax Technologies, Inc., HIPRA, S.A., Indian Immunologicals Ltd., KM Biologics Co., Ltd., Kyoto Biken Laboratories, Inc., Malaysian Vaccines & Pharmaceuticals Sdn Bhd., Medgene Labs, Merck & Co., Inc., Nisseiken Co., Ltd., PBS Animal Health, Phibro Animal Health Corporation, Virbac SA, Yenher Agro-Products Sdn. Bhd., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Porcine Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Indication
  • Arthritis
  • Diarrhea
  • Porcine Circovirus Associated Disease
  • Porcine Reproductive & Respiratory Syndrome
  • Swine Influenza

• Technology
  • Conjugate Vaccines
  • DNA Vaccines
  • Inactivated Vaccines
  • Live attenuated Vaccines
  • Recombinant Vaccines
  • Toxoid Vaccines

• End User
  • Hog/Pig Production Farm
  • Veterinary Clinics/Hospitals

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Porcine Vaccines Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Porcine Vaccines Market?

3. What are the technology trends and regulatory frameworks in the Porcine Vaccines Market?

4. What is the market share of the leading vendors in the Porcine Vaccines Market?

5. Which modes and strategic moves are suitable for entering the Porcine Vaccines Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in Prevalence of Swine Diseases Worldwide
    • 5.1.1.2. Increasing Demand for High-Quality Pork Meat
    • 5.1.1.3. Government Initiatives to Support Animal Health
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost of Porcine Vaccine Development and Complex Storage Issues
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological Advancements in Porcine Vaccine
    • 5.1.3.2. Favorable Investment Landscape For Production of Novel Porcine Vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Limited Availability and Awareness Along with Side Effects Associated with Porcine Vaccines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Growing innovations in recombinant vaccines due to advancements in genetic engineering and molecular biology technologies
  • 5.2.2. End User: Growing need for mass vaccination programs in the hog/pig production farm
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of Russia-Ukraine Conflict
• 5.5. Cumulative Impact of High Inflation
• 5.6. Porter's Five Forces Analysis
  • 5.6.1. Threat of New Entrants
  • 5.6.2. Threat of Substitutes
  • 5.6.3. Bargaining Power of Customers
  • 5.6.4. Bargaining Power of Suppliers
  • 5.6.5. Industry Rivalry
• 5.7. Value Chain & Critical Path Analysis
• 5.8. Regulatory Framework Analysis
• 5.9. Client Customization

6. Porcine Vaccines Market, by Indication

• 6.1. Introduction
• 6.2. Arthritis
• 6.3. Diarrhea
• 6.4. Porcine Circovirus Associated Disease
• 6.5. Porcine Reproductive & Respiratory Syndrome
• 6.6. Swine Influenza

7. Porcine Vaccines Market, by Technology

• 7.1. Introduction
• 7.2. Conjugate Vaccines
• 7.3. DNA Vaccines
• 7.4. Inactivated Vaccines
• 7.5. Live attenuated Vaccines
• 7.6. Recombinant Vaccines
• 7.7. Toxoid Vaccines

8. Porcine Vaccines Market, by End User

• 8.1. Introduction
• 8.2. Hog/Pig Production Farm
• 8.3. Veterinary Clinics/Hospitals

9. Americas Porcine Vaccines Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Porcine Vaccines Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Porcine Vaccines Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Zoetis Launches Circomax In The UK
  • 12.3.2. Merck Animal Health Launches 3-In-One Swine Vaccine
  • 12.3.3. Elanco is Exclusive U.S. Distributor of Aptimmune's PRRS Killed Autogenous Vaccine

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio